This article discusses peptides as research compounds. It is not medical advice.
A clinician I spoke with at a metabolic research meeting last year mentioned an unusual observation: a patient using a growth hormone fragment for weight loss reported a sudden disinterest in evening wine. The compound was AOD-9604, a modified peptide originally developed as an anti-obesity agent. The clinician wondered whether the effect was incidental, placebo-driven, or something more specific. That anecdote mirrors a broader question now circulating in research communities: can peptides designed for fat metabolism also alter alcohol-seeking behavior the way GLP-1 receptor agonists appear to do?
This article discusses peptides as research compounds. It is not medical advice.
Semaglutide and tirzepatide have generated substantial interest for their apparent ability to reduce alcohol consumption in preclinical models and early human observations. A 2023 case series in Scientific Reports described reduced Alcohol Use Disorders Identification Test scores in six patients treated with semaglutide for weight loss (PubMed). Those findings align with rodent studies showing that GLP-1 receptor activation decreases dopamine release in the nucleus accumbens after alcohol exposure. But AOD-9604 does not act on GLP-1 receptors. Its mechanism involves a fragment of human growth hormone, specifically the lipolytic region, with no known direct effect on reward circuitry. The hypothesis that AOD-9604 could curb drinking therefore requires a different biological explanation, if one exists at all.
What the metabolic peptide sub-niche covers
Research on AOD-9604 sits within a sub-niche focused on fat oxidation, lipolysis, and body recomposition. The peptide is a modified sequence of amino acids 177-191 of human growth hormone, altered to remove the diabetogenic and growth-promoting effects while retaining the fat-burning signal. A 2001 study in Obesity Research showed that AOD-9604 stimulated lipolysis in rat adipocytes and reduced body fat in obese mice without affecting blood glucose (PubMed). Later human trials, including a 2004 phase 2b study, found modest weight loss compared to placebo but did not meet primary endpoints for regulatory approval. The compound remains an unapproved research peptide, often sold through gray-market channels.
By contrast, GLP-1 receptor agonists like semaglutide and tirzepatide have received FDA approval for type 2 diabetes and obesity. Their effects on alcohol intake are considered off-target or secondary, but the evidence is growing. A 2022 review in Frontiers in Pharmacology summarized preclinical data showing that GLP-1 analogs reduce alcohol self-administration in rodents and nonhuman primates (PubMed). The proposed mechanism involves GLP-1 receptors in the brainstem and mesolimbic system, areas that regulate satiety and reward. AOD-9604 does not engage these receptors, which makes any comparison to GLP-1s scientifically premature.
Other peptides in this sub-niche include CJC-1295, a growth hormone secretagogue, and hexarelin, a ghrelin receptor agonist. Neither has shown consistent effects on alcohol consumption in published research. Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, is currently in phase 3 trials for obesity and may have indirect effects on alcohol intake through appetite suppression. However, no peer-reviewed study has tested AOD-9604 for alcohol cravings or drinking behavior. The research gap is wide.
Key compounds in this area
Semaglutide is the most studied GLP-1 agonist for alcohol-related outcomes. A 2023 randomized controlled trial in JAMA Psychiatry found that semaglutide reduced alcohol drinking in patients with alcohol use disorder and obesity, though the sample was small (PubMed). Tirzepatide, a dual GIP/GLP-1 agonist, showed similar effects in a 2024 preclinical study using alcohol-preferring rats (PubMed). Retatrutide has not been tested for alcohol outcomes in humans, but its glucagon component may enhance satiety and reduce reward-seeking behavior.
AOD-9604 remains an outlier. Its original developer, Metabolic Pharmaceuticals, conducted clinical trials for obesity and cartilage repair but never investigated alcohol use. A 2019 review of growth hormone fragments noted that AOD-9604 does not cross the blood-brain barrier in significant amounts, which limits any direct central nervous system effect (PubMed). That finding alone argues against a GLP-1-like mechanism for alcohol craving reduction. If AOD-9604 influences drinking, the pathway would likely be peripheral, perhaps through altered lipid metabolism or indirect hormonal feedback.
CJC-1295 and hexarelin are sometimes stacked with AOD-9604 for body recomposition, as discussed in a separate article on AOD-9604 and CJC-1295 stack research. Neither compound has a plausible mechanism for reducing alcohol cravings. Hexarelin, as a ghrelin agonist, might theoretically increase appetite and reward sensitivity, which could worsen drinking behavior. No published study has tested that possibility.
What the research consensus looks like
For GLP-1 receptor agonists, the research consensus is cautiously optimistic but far from settled. A 2024 meta-analysis in Addiction pooled data from 12 studies and found a significant reduction in alcohol consumption among GLP-1 users compared to placebo, with a moderate effect size (PubMed). The authors cautioned that most studies were short-term and included patients with comorbid obesity or diabetes, which may confound results. The VA trial mentioned in a related article on semaglutide for alcohol use disorder is expected to provide more definitive data by 2026.
For AOD-9604, there is no research consensus on alcohol effects because no studies exist. The peptide was never approved for any indication, and its clinical development stalled after a 2006 phase 2b trial for obesity failed to show significant weight loss over placebo (PubMed). Since then, AOD-9604 has appeared primarily in gray-market products and bodybuilding forums. The FDA has issued warning letters to companies selling AOD-9604 as a dietary supplement or unapproved drug, citing lack of safety and efficacy data (FDA warning letter). Those enforcement actions underscore the regulatory risk of using this peptide outside approved research settings.
The consensus on AOD-9604 for fat loss is mixed. Some early human studies showed a trend toward reduced abdominal fat, but the effect was small and inconsistent. A 2020 review in Peptides concluded that growth hormone fragments like AOD-9604 have limited clinical utility due to poor bioavailability and short half-life (PubMed). No credible researcher has proposed AOD-9604 as a treatment for alcohol use disorder, and the mechanistic gap is substantial.
Where the active research is
Active research on alcohol and peptides centers on GLP-1 receptor agonists. The National Institute on Alcohol Abuse and Alcoholism is funding several trials of semaglutide for alcohol use disorder, including a large multisite study expected to enroll 300 participants. A 2024 trial in Nature Medicine reported that semaglutide reduced heavy drinking days by 40% in patients with alcohol use disorder and obesity, compared to 20% for placebo (PubMed). Tirzepatide is being tested in a similar population, with results expected in 2025.
For AOD-9604, active research is nearly nonexistent. A search of ClinicalTrials.gov in early 2025 found no registered trials for AOD-9604 in any indication. The peptide is occasionally mentioned in preclinical studies of lipolysis or cartilage repair, but no investigator has proposed testing it for alcohol-related outcomes. The lack of patent protection and regulatory approval makes pharmaceutical investment unlikely. Most AOD-9604 use occurs in unregulated settings, which raises safety concerns that are detailed in a separate article on semaglutide safety after compounding pharmacy concerns.
Retatrutide is a newer compound that may indirectly affect alcohol intake through its glucagon receptor agonism. A 2024 phase 2 trial reported that retatrutide reduced alcohol consumption in a subset of patients with obesity and alcohol use disorder, but the finding was exploratory (PubMed). The triple-agonist mechanism is discussed in more detail in an article on semaglutide vs. retatrutide. Whether AOD-9604 could be combined with a GLP-1 agonist to enhance alcohol-related effects is unknown and untested.
Where the gaps are
The most obvious gap is the complete absence of human or animal data on AOD-9604 and alcohol cravings. No published study has administered AOD-9604 to alcohol-consuming rodents or humans and measured drinking behavior. The peptide's poor brain penetration makes a direct central effect unlikely, but peripheral mechanisms cannot be ruled out. For example, AOD-9604 might alter circulating free fatty acids or ketone bodies, which could indirectly affect brain reward signaling. That hypothesis is speculative and unsupported by data.
Another gap is the lack of long-term safety data for AOD-9604 in any population. The original clinical trials enrolled fewer than 1,000 patients and lasted less than six months. Adverse events were generally mild, but no post-marketing surveillance exists because the drug was never approved. The FDA has repeatedly warned that AOD-9604 is not a dietary ingredient and cannot be legally sold as a supplement (FDA AOD-9604 page). Researchers interested in this peptide must navigate significant regulatory hurdles.
Finally, the comparison between AOD-9604 and GLP-1 agonists for alcohol use is scientifically invalid at this time. GLP-1 receptor agonists have a plausible mechanism, accumulating preclinical and clinical evidence, and ongoing large trials. AOD-9604 has none of these. Anyone suggesting that AOD-9604 can curb drinking like semaglutide is making an unsupported leap. The research community has not endorsed such a claim, and no peer-reviewed publication supports it.
If you are pregnant, nursing, or under medical treatment, consult your physician before considering any compound covered in this article.
Common questions
Does AOD-9604 reduce alcohol cravings?
No published study has tested AOD-9604 for alcohol cravings or drinking behavior. The peptide does not act on GLP-1 receptors and has poor brain penetration, which makes a direct effect on reward circuitry unlikely. Any reports of reduced alcohol intake in AOD-9604 users are anecdotal and unverified. Researchers have not proposed a plausible mechanism by which this growth hormone fragment would alter alcohol-seeking behavior. Until controlled studies are conducted, the answer is unknown.
How does semaglutide reduce alcohol consumption?
Semaglutide activates GLP-1 receptors in the brainstem and mesolimbic system, areas that regulate satiety and reward. Preclinical studies show that GLP-1 receptor activation decreases dopamine release in the nucleus accumbens after alcohol exposure, which may reduce the rewarding properties of alcohol. A 2023 trial in JAMA Psychiatry found that semaglutide reduced alcohol drinking in patients with alcohol use disorder and obesity. The effect appears independent of weight loss, though the exact mechanism is still under investigation.
Is AOD-9604 approved by the FDA for any use?
No. AOD-9604 is not approved by the FDA for any indication, including weight loss or alcohol use disorder. The FDA has issued warning letters to companies selling AOD-9604 as a dietary supplement or unapproved drug, citing lack of safety and efficacy data. The peptide is considered a research chemical and cannot be legally marketed for human consumption in the United States. Researchers must obtain appropriate approvals to study it.
Can AOD-9604 be stacked with GLP-1 agonists for alcohol reduction?
There is no research on combining AOD-9604 with GLP-1 agonists for alcohol reduction or any other indication. AOD-9604 is sometimes stacked with CJC-1295 or tirzepatide for body recomposition, but those combinations are unapproved and untested in clinical trials. The safety of such stacks is unknown, and the FDA has warned against using unapproved peptides. Anyone considering such a combination should consult a physician and review the regulatory risks.
What are the risks of using AOD-9604 from gray-market sources?
Gray-market AOD-9604 may be contaminated, mislabeled, or of unknown purity. The FDA has found that many unapproved peptide products contain no active ingredient or harmful impurities. Because AOD-9604 is not manufactured under pharmaceutical quality standards, users cannot verify what they are injecting. Adverse events may go unreported, and no long-term safety data exist. The regulatory and health risks are significant, as detailed in a related article on AOD-9604 and tirzepatide stack.
This article discusses peptides as research compounds. It is not medical advice.